Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Human Syndecan-4 ELISA Kit

Click to view available options
Quantity:
10 x 96 Tests
5 x 96 Tests
96 Tests
Description
Human Syndecan-4 quantitates human Syndecan-4 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Syndecan-4.
Syndecans are type I integral membrane proteoglycans that are involved in cell-extracellular matrix adhesion and growth factor binding. Syndecan 1 is a matrix receptor which binds to Collagens, Fibronectin and Thrombospondin. Syndecan 1 and Syndecan 3 interact with MK (midkine), a growth/differentiation factor involved in embryogenesis. Syndecan 2 is highly expressed at areas of high morphogenetic activity, such as epithelial-mesenchymal interfaces and the prechondrogenic and preosteogenic mesenchymal condensations. Syndecan 4 functions cooperatively with integrins in the processes of cell spreading and focal adhesion assembly.

Specifications
Specifications
Accession Number | AA959608; Amphiglycan; AW108331; MGC22217; RATRYUDOCA; RYUDOCA; ryudocan; ryudocan amphiglycan; ryudocan core protein; Ryudocan/syndecan 4; S4; Sdc4; SYND4; syndecan 4; syndecan 4 (amphiglycan, ryudocan); syndecan proteoglycan 4; syndecan-4 |
Assay Range | 6.14 to 1,500 pg/mL |
Assay Sensitivity | 6 pg/mL |
Conjugate | HRP |
Product Type | ELISA |
Sample Type | Plasma, Serum, Supernatant |
For Use With (Equipment) | Colorimetric Microplate Reader |
Gene ID (Entrez) | 6385 |
Gene Symbol | Sdc4 |
Interassay CV | <12% |
Show More |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction